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Most patients with advanced or metastatic cancer experience pain and despite several guidelines, undertreatment is well
documented. A multicenter, open-label, prospective, non-randomised study was launched in Italy in 2006 to evaluate the
epidemiology, patterns and quality of pain care of cancer patients. To assess the adequacy of analgesic care, we used a standardised
measure, the pain management index (PMI), that compares the most potent analgesic prescribed for a patient with the reported level
of the worst pain of that patient together with a selected list of clinical indicators. A total of 110 centres recruited 1801 valid cases.
61% of cases were received a WHO-level III opioid; 25.3% were classified as potentially undertreated, with wide variation (9.8–
55.3%) according to the variables describing patients, centres and pattern of care. After adjustment with a multivariable logistic
regression model, type of recruiting centre, receiving adjuvant therapy or not and type of patient recruited (new or already on follow-
up) had a significant association with undertreatment. Non-compliance with the predefined set of clinical indicators was generally
high, ranging from 41 to 76%. Despite intrinsic limitations of the PMI that may be considered as an indicator of the poor quality
of cancer pain care, results suggest that the recourse to WHO third-level drugs still seems delayed in a substantial percentage
of patients. This delay is probably related to several factors affecting practice in participating centres and suggests that the quality of
cancer pain management in Italy deserves specific attention and interventions aimed at improving patients’ outcomes.
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Pain is a major problem for patients with cancer. Meta-analyses
report that most patients with advanced or metastatic cancer
experience pain (Hearn and Higginson, 2003; van den Beuken-van
Everdingen et al, 2007). Although several guidelines for cancer
pain management have been published since 1986 (Jacox et al,
1994; WHO, 1996; Hanks et al, 2001; Cohen et al, 2003; SIGN,
2008), undertreatment is well documented and can reach 82% of
patients in some settings (Di Maio et al, 2004). A recent systematic
review based on 26 papers published from 1994 to 2007 suggests
that nearly one of two patients with cancer pain is undertreated
with a wide variability across studies and settings (Deandrea et al,
2008). Undertreatment is usually attributed to inappropriate use of
opioids on account of several reasons related to the healthcare
provider, patient, family, institution and society (Maltoni, 2008),
where fear of opioids may be the most important determinant
from the patient’s point of view (Reid et al, 2008).
In Italy, opioid consumption rates are yet among the lowest in
Europe (De Conno et al, 2005), although last year there was a small
increase, mainly because of a change in the type of drugs
prescribed than to an increase in the number of patients treated
(Osservatorio Nazionale sull’impiego dei farmaci, 2007). As
recently pointed out, poor information and communication may
be a further barrier to a correct access to analgesic and palliative
care and to hospice admission (Harrington and Smith, 2008).
To improve the quality of cancer pain management, the Mario
Negri Institute implemented a project on 2004 in Italy (Apolone
et al, 2004, 2006a), and an Outcome Research study was launched
in 2006. The objectives were (a) to describe a large cohort of cancer
patients in terms of pain characteristics, patterns of care and
patient-reported outcomes; (b) to assess the quality of analgesic
treatments in terms of congruence between the reported level of
pain intensity of patients and the potency of the prescribed
analgesic drug; (c) to compare the effects of various analgesic
options, using appropriate statistical methods, such as the
propensity score. This study reports on details about the design
of the study, the type of patients recruited, the analgesic drugs
prescribed and the quality of analgesic care administered.
PATIENTS AND METHODS
Study design and patients
Background and methods are described elsewhere (Apolone et al,
2006a,b, 2008). Briefly, the data reported here were collected as
part of a multicentre, open-label, prospective, non-randomised
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sstudy. Each centre admitted up to 25 patients with diagnostic
evidence of advanced/metastatic solid tumour; persistent pain, of
any degree of intensity related to cancer, requiring or already on
analgesic treatment; age X18 years; life expectancy more than 1
month; and able to read, understand and provide informed
consent to participate.
After enrolment/inclusion, the following screening assessments
were carried out and recorded weekly for the first month, with a
final visit at week 12 (at the end of the study): (a) medical history
including cancer history, (b) physical examination, (c) record of
medications and recent therapies, including analgesic consump-
tion, (d) pain and symptom assessment, (f) patients’ and
physicians’ satisfaction with pain treatment and (g) patient’s
self-reported quality of life.
Outcomes and endpoints
Patients’ and physicians’ reports were collected using standardised
forms at scheduled visits. Self-administered questionnaires were com-
pleted when the patient attended regular visits at the centre or during
admission or at home depending on the setting of care. Investigators
recorded information about patients and disease, pain medications
and type and number of rescue doses in a case report form.
Pain characteristics (intensity, relief and so on) were the
primary outcome measures. Other patient-reported outcomes
were collected too, such as satisfaction with care, quality of life
and symptoms. Pain was measured using five items from the
Italian version of the Brief Pain Inventory (Caraceni et al, 1996)
assessing intensity of worst, present, least and average pain and
pain relief with an 11-point numerical rating scale.
We used two methods to evaluate the analgesic undertreatment.
First, we applied the pain management index (PMI), developed by
Cleeland et al (1994). According to the World Health Organisa-
tion’s (WHO) guidelines for the management of pain in cancer,
treatment is considered adequate when there is congruence
between the reported level of pain of the patient and the potency
of the prescribed analgesic drug (its place on the WHO analgesic
ladder; WHO, 1996). The PMI compares the most potent analgesic
prescribed for a patient with the reported level of the worst pain of
that patient.
To construct the index, we determined which of four levels of
analgesic drug therapy was the most potent one used: 0, no
analgesic drug; 1, a non-opioid (e.g., a non-steroidal anti-
inflammatory drug); 2, a weak opioid (e.g., codeine or tramadol);
and 3, a strong opioid (e.g., morphine, fentanyl, buprenorphine,
oxycodone and so on). We then determined the patient’s level of
pain from the Brief Pain Inventory (1–3, mild; 4–7, moderate;
8–10, severe). No pain was scored as 0; mild pain, 1; moderate
pain, 2; and severe pain, 3. The PMI, computed by subtracting the
pain level from the analgesic level, ranges from  3 (a patient with
severe pain receiving no analgesic drugs) to þ3 (a patient
receiving morphine or an equivalent and reporting no pain).
Negative scores are considered to indicate pain undertreatment,
and scores of 0 or higher are considered a conservative indicator of
acceptable treatment (see Figure 1).
As the PMI provides only a rough estimate of how pain is treated
in a sample taking into account only some attributes of the pain
characteristics (Deandrea et al, 2008), we also assembled a list of
clinical indicators to capture the appropriateness of the analgesic
care delivered more directly. Operationally, we identified four
specific clinical conditions where there was evidence that pain
should be treated with a specific approach according to available
guidelines: presence of episodes of breakthrough pain to be treated
with a strong opioid as rescue/escape therapy, presence of
neuropathic pain to be treated with a specific adjuvant drug, pain
with intensity higher than 7 points, calling for a strong opioid as
around-the-clock therapy, and presence of bone metastasis to be
treated with bisphosphonates, (Hanks et al, 2001; Wong and
Wiffen, 2002; CEVEAS, 2004; SIGN, 2008). Then, we estimated the
proportion of patients in each group who did not receive the
recommended therapy, as additional indicators of the quality of
analgesic therapy. Frequencies were then associated with some
variables, such as type of patient and recruiting centre.
Given the large number of centres, we used a web-based system
to optimise the handling of all aspects of the clinical study,
including data entry, quality assurance and validation. A general
data entry engine for clinical trials developed by the Mario Negri
Institute was used, which was compliant with current laws
concerning ethical and regulatory issues (Clivio et al, 2006).
Before implementation, it was tested with a pilot feasibility study
in 130 centres in 2005.
Statistical analysis
On the basis of the literature and the results of the pilot study in
2005, we assumed that 100 centres during a 2-month inception
period (recruitment) could see and evaluate up to 2500 eligible
cases. We also assumed that at least half would already be receiving
a WHO level III treatment and most of the others would eventually
need a WHO level III analgesic during the longitudinal evaluation
period.
There were no formal estimates of the proportion of cases who
might be classified as undertreated at inclusion, although, on the
basis of a systematic review of the literature pertaining to the PMI
(Deandrea et al, 2008), it was expected that up to 40% of patients
might be receiving, at the time of study inclusion, an analgesic
treatment not adequate to their intensity of pain. All patients
enrolled in the study and eligible were included in the present
analysis.
In the descriptive analysis, absolute frequency was used for
categorical variables and central trend and dispersion measure-
ments (mean, median and s.d.) for quantitative continuous
variables. When comparing groups, w
2-tests for associations were
used for categorical variables, such as whether or not patients
experienced a given event. For continuous variables, such as mean
differences in pain intensity, t-tests or one-way-analysis of
variance, were used. For binary dependent variables, such as
whether or not the patient had an analgesic undertreatment
according to the PMI, estimates of association with potential
independent variables were expressed in terms of odds ratios
(ORs). After univariate analysis, a logistic model was fitted using
maximum likelihood estimation to express the odds of each
variable relative to the reference category, after adjustment for all
other covariates. For example, the risk of being classified as
Pain intensity
WHO analgesic drug level
No pain (0)
No drugs NSAID Weak opioids Strong opioids
0
(0) (I) (II) (III)
0
0
0
–1
+1 +2
+2
+3
+1
+1 –2 –1
–1 –2 –3
Mild (1-3)
Moderate (4-7)
Severe (8-10)
Figure 1 Pain management index.
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sundertreated for a patient with 70 years of age or more was
compared to one younger than 51 years, given the same sex, type
of cancer and analgesic adjuvant therapy. In addition, 95%
confidence intervals of the ORs were computed.
Given the observational nature of the study, the relatively large
sample size and the number of statistical tests, P-values must be
considered with cautions as merely suggestive of a trend.
Ethical considerations
The study complied with Italian requirements for observational
studies. The protocol was approved by the local research ethics
committees of participating centres. All patients gave written
informed consent to participate in the study. The full study
protocol was published in an open-access journal before the study
started (Apolone et al, 2006b).
RESULTS
As shown in Figure 2, 110 centres recruited 1801 valid cases that
constitute the baseline cross-sectional sample, from February 2006
to March 2007. There were 1461 patients with complete data at 28
days and they form the longitudinal sample. This study focuses on
the baseline sample.
As shown in Table 1, patients recruited were more frequently
male, and had severe pain (mean worst pain at baseline 6.8). Half
had bone metastasis, episodes of breakthrough pain and were still
on active anticancer treatment. The most frequent primary cancers
were lung, breast and colorectal cancers. Nearly two-thirds were
recruited by oncologic centres, and the majority were not aware of
their prognosis. Most had already been admitted at the centre
when enrolled in the study. In all, 61% of patients were received a
WHO-level III opioid, fentanyl and buprenorphine transdermal
delivery systems being the most widely prescribed (in about 39%
of cases); 47% received some kind of rescue/escape therapy, which
was an anti-inflammatory drug in 53% of cases; oral morphine was
the most widely prescribed strong opioid as recue therapy. A total
of 60% also received some kind of adjuvant analgesic therapy.
We first assembled the PMI using all four items of the Brief Pain
Inventory. Table 2 shows, as expected, that different pain items
generated different undertreatment estimates (8.9–25.3%). As
recommended by Cleeland et al (1994), we used the worst pain
item as main outcome. According to the literature suggesting wide
variations on the basis of several variables related to patients,
centres and settings (Deandrea et al, 2008), we first conducted a
bivariate analysis to identify the potential predictors of under-
treatment, then a multivariable analysis to estimate the effect of
each potential confounder on the association between predictors
and occurrence of undertreatment. Tables 3–5 report the results of
both analyses.
When patients were classified according to the time of the
follow-up or treatment before inclusion (new incident cases vs
patients already in follow-up at the centre), there was a clear
tendency: the proportion of undertreatment ranged from 44.7 to
20.2% with a consistent and statistically significant gradient
(Po0.0001). Among the other potential predictors tested with
univariate analyses, the absence of bone metastasis and ongoing
chemotherapy, being recruited in pain and palliative centres,
having a colorectal cancer, and not receiving adjuvant analgesic
therapy, were significantly associated with a higher probability of
being classified as undertreated (OR¼41.2 and Po0.05). After
multivariable logistic regression, only type of recruiting centre
(Po0.01), receiving adjuvant therapy or not (Po0.001), and type
of patient recruited (new or already on follow-up; Po0.01) showed
a significant association with undertreatment. To describe the
effect of these three variables better, we assembled a new
composite variable comprising all the possible mutually exclusive
combinations of the original predictors transposed to 12 possible
levels where we estimated the prevalence of undertreatment.
Estimates ranged from 9.8 (patients already admitted to hospice,
receiving adjuvant therapy) to 55.3% (new cases admitted to pain
or palliative care centre, not receiving adjuvant treatment). Figure 3
confirms that each of the three variables actually has an effect on
the occurrence of undertreatment, and within each type of
recruiting centre, the other two variables may stratify patients
with different frequency. Nevertheless, patients in a hospice had a
lower prevalence (range¼9.8–30.4%) than those in oncology
Participating centres 
(160)
Centres 
not compliant with protocol 
(13/88 patients)
Centres 
compliant with protocol 
 (110/1842 patients)
Recruiting centres
(123/1930 patients)
Patients
not eligible to protocol 
(41 patients)
Cross-sectional sample
for descriptive and
epidemiologic purposes 
(1801 patients)
Longitudinal sample  
for outcome evaluation 
(1461 patients) 
Figure 2 Synopsis of the stages of the study.
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scentres (16.3–39.3%) and pain and palliative centres (11.8–
55.3%).
Table 6 shows the prevalence of patients receiving the treatment
that we considered appropriate for each specific condition, and the
associations with type of patient and type of centre. Non-
compliance with the treatments identified was generally high,
with some variability according to the type of patient and the
recruiting centre. New cases had higher non-compliance rates in
general. In patients with neuropathic pain, non-compliance was
higher in oncology centres; in patients with severe worst pain, non-
compliance rates were higher in palliative and pain centres.
DISCUSSION
Advances in diagnosis and therapy have extended the life
expectancy of cancer patients, but for most of them, the last part
of their life is impaired by pain, depression and other symptoms
Table 1 Characteristics of patients at baseline (n¼1801)
Characteristics % Mean, s.d.
Age 63.9, 12.1
Female 47.3
Karnofsky PS, o50 11.5
Primary tumour
Lung 21.8
Breast 15.9
Colorectal 13.7
Prostate 7.9
Gynecological 6.1
Pancreas 6.0
Genitourinary 6.1
Stomach 5.5
Head and neck 4.5
Liver 1.2
Others 9.9
Unknown 1.4
Bone metastasis 46.8
Earlier surgery 58.0
Earlier chemotherapy 65.2
Earlier hormonotherapy 20.0
Earlier radiotherapy 40.3
Others 5.4
Ongoing chemotherapy 49.0
Patients aware of prognosis (reported by physician) 30.3
Type of recruiting centre
Oncology centre 59.4
Palliative care 17.0
Pain centre 15.1
Hospice 7.7
Others 0.8
Time of recruiting
New cases 25.7
Already admitted 74.3
Pain intensity (0–10)
Worst (previous week) 6.8, 2.2
Mean (previous week) 4.5, 2.0
Current 3.4, 2.7
Least (previous week) 2.6, 2.0
Pain intensity (according to WHO)
None 1.1
Mild 26.0
Moderate 65.9
Severe 7.1
Pain relief (0–100) 55.1, 26.4
Patients with breakthrough pain 48.4
Patients with neuropathic pain 25.7
Type of analgesic care
Around the clock therapy
None 5.9
Only NSAID 8.8
Only weak opioids 10.6
NSAID with weak opioids 14.1
One strong opioid 38.3
NSAID/weak opioid+strong opioid 19.2
More than one strong opioid 3.1
Rescue therapy
None 53.2
Only NSAID 24.9
Table 1 (Continued)
Characteristics % Mean, s.d.
Only weak opioids 3.8
NSAID with weak opioids 2.9
One strong opioid 11.8
NSAID/weak opioid+strong opioid 3.2
More than one strong opioid 0.2
Adjuvant therapy
Corticosteroids 40.1
Anticonvulsants 15.8
Antidepressants 10.8
Bisphosphonates 18.5
Table 2 Percentages of patients with negative PMI score for different
pain items (from Brief Pain Inventory)
Time of recruiting
Pain All Already admitted New patients
Worst pain 25.3 20.4 38.3
Least pain 8.9 6.0 16.7
Current pain 12.2 8.5 22.0
Mean pain 14.6 11.3 23.7
Overall pain (four items) 14.0 11.1 21.8
Table 3 Percentages of patients with negative PMI scores according to
the type of recruitment (new patients or patients already admitted at the
time of inclusion in the study)
Days since admission to the centre
0 (new patients) 1–7 8–27 427
N 282 171 210 1101
PMI negative scores
n 126 48 46 222
% 44.7 28.1 21.9 20.2
Cochran–Armitage trend test w
2¼8.124
Po0.0001
Heterogeneity test Statistic¼73.8092
Po0.0001
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srelated to the disease and treatments that become major
contributors to suffering. Considerable evidence from clinical
experience shows that cancer pain may be controlled in up to 90%
cases with available therapies (Ventafridda et al, 1987; Grond et al,
1996; Mercadante, 1999). The epidemiology of cancer pain and
related treatments in Italy is not well documented, but under-
treatment is to be expected as strong opioids are prescribed only to
a small proportion of eligible patients. (De Conno et al, 2005;
Osservatorio Nazionale sull’impiego dei farmaci, 2007). This study
reporting the results of an observational study produced a
significant picture of the management of cancer pain for an
unselected population of cancer patients in the care of different
Italian specialist facilities (oncology clinics, pain and palliative
care and hospice centres). Forthcoming studies will describe the
longitudinal change over time of both therapeutic and outcome
variables and will compare the effectiveness of different analgesic
strategies (Apolone et al, 2006b).
The main aim of this analysis was to estimate the quality of
analgesic drug regimens across different settings. We applied the
PMI as recommended by Cleeland et al (1994) using the worst
intensity of pain to calculate the score. By changing the pain
measure criteria, it yields figures which cannot be fully compared,
as suggested by earlier research (de Wit et al, 1999).
The prevalence of undertreatment found in this study (25% in
the whole sample and up to 55% in some groups) compares the
earlier results ranging from as low as 7–9% in a survey in the
United Kingdom (Russell et al, 2006) to 82% in a sample of non-
small cell lung cancer patients entering clinical trials in Italy (Di
Maio et al, 2004), with the weighted overall mean of 43% across 26
different studies (Deandrea et al, 2008).
When the factors associated with negative PMI were examined
in this study, undertreatment tended to be lower according to the
year of publication, showing a time trend between articles
published before and after 2000; it was also associated with
socioeconomic and geographic factors: patients coming from
Asian countries and patients with lower socioeconomical status
had the highest risk of undertreatment. Other factors that predict a
negative PMI consistently were having a less advanced disease and
the discrepancy between the patient’s and physician’s assessments
of pain intensity (Russell et al, 2006; Deandrea et al, 2008).
Table 4 Percentages of patients with negative PMI scores according to
selected variables
N % OR 95% CI P-value
Age (years)
o51 254 22.8 1.00 — —
51–60 402 25.4 1.15 0.79–1.66 0.4610
61–70 558 23.5 1.04 0.73–1.47 0.8415
470 583 28.0 1.31 0.93–1.85 0.1227
Sex
Male 947 24.2 1.00 — —
Female 850 26.5 1.13 0.91–1.40 0.2650
Bone metastasis
Yes 842 22.3 1.00 — —
No 955 27.9 1.34 1.08–1.67 0.0072
Ongoing chemotherapy
Yes 883 23.0 1.00 — —
No 914 27.5 1.27 1.02–1.57 0.0294
Type of recruiting centre
Oncology centre 1066 23.7 1.48 0.93–2.35 0.0978
Pain center 271 34.0 2.44 1.47–4.05 0.0006
Palliative care 307 26.1 1.67 1.01–2.78 0.0471
Hospice 138 17.4 1.00 — —
Others 15 33.3 2.38 0.74–7.58 0.1440
Type of cancer
a
NSCLC 391 22.5 1.15 0.67–1.98 0.6214
Breast 287 23.7 1.23 0.70–2.15 0.4757
Colorectal 247 31.2 1.79 1.02–3.13 0.0416
Prostate 142 21.1 1.06 0.56–2.00 0.8617
Pancreas 108 24.1 1.25 0.65–2.42 0.5037
Stomach 99 20.2 1.00 — —
Breakthrough pain
Yes 870 24.2 1.00 — —
No 927 26.4 1.14 0.92–1.41 0.2409
Neuropathic pain
Yes 455 24.8 1.00 — —
No 1314 25.2 1.02 0.80–1.30 0.8806
Analgesic adjuvant therapy
Yes 1078 18.1 1.00 — —
No 719 36.0 2.55 2.05–3.17 o0.0001
aOnly cancers with frequency 45%.
Table 5 Multivariate association (multivariable logistic regression)
between selected variables and PMI negative scores
OR 95% CI P-value
Age (years)
o51 1.00 0.69–1.46 0.9916
51–60 1.04 0.75–1.44 0.8021
61–70 1.00 — —
470 1.21 0.91–1.62 0.1870
Sex
Male 1.00 — —
Female 1.21 0.96–1.53 0.1082
Bone metastasis
Yes 1.00 — —
No 1.05 0.82—1.35 0.6795
Ongoing chemotherapy
Yes 1.00 — —
No 1.17 0.91–1.51 0.2195
Type of recruiting centre
Palliative care+pain centre 2.09 1.27–3.45 0.0038
Oncology centre 2.09 1.26–3.45 0.0041
Hospice 1.00 — —
Type of cancer
Pancreas 1.00 — —
Colorectal 1.43 0.82–2.48 0.2047
Gynecologic 1.42 0.80–2.51 0.2282
Others 1.15 0.69–1.91 0.5865
Breakthrough pain
Yes 1.00 — —
No 1.09 0.86–1.37 0.4793
Neuropathic pain
Yes 1.14 0.87–1.49 0.3514
No 1.00 — —
Analgesic adjuvant therapy
Yes 1.00 — —
No 2.40 1.89–3.04 o0.0001
Time of recruiting
Already admitted 1.00 — —
New cases 2.46 1.88–3.20 o0.0001
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sThis study shows that the baseline PMI scores are also
influenced by the time of referral. Patients just referred to a
centre had negative PMI more often (41%) than patients already
followed by the centre. This factor has been underestimated in the
literature and it should, therefore, be stressed that the patient’s
pain history is a significant variable in evaluating epidemiological
and therapy-related information. A selection bias can also have
occurred in our study as physicians may have referred those
patients who needed expert advice for treating their pain, although
20% of negative PMI persisted also in patients referred to the
centre since a long time (Table 3).
In this study, the setting of care and receiving an adjuvant
analgesic drug treatment were also predictors of the PMI status.
Being admitted to a hospice and the use of an adjuvant drug were
in fact independently associated with more adequate analgesic
treatments. These observations might be interpreted as indicative
of a delay of starting strong opioids influenced by attitudes of
practice and setting of care. Time of patient referral to the centre,
considered as very important, is not enough to explain pain and
pain treatment history. Organisation and expertise in pain
management and monitoring by different specialists and in
different settings, such as an in-patient hospice or outpatient pain
clinic, probably influence the recourse to more potent drugs.
The use of adjuvants for neuropathic pain is an indicator of
compliance with available guidelines (SIGN, 2008), and perhaps its
association with more appropriate opioid use is consistent in
explaining individual differences among operators even in
apparently similar settings.
Although the usefulness of the PMI is proved by the large
number of studies that have used this score since 1994, some
drawbacks are well known (Deandrea et al, 2008) and others may
be derived from our analysis. It takes into account only one
characteristic of pain (the intensity) and the most potent opioid
prescribed, but does not reflect other pain characteristics, opioid
titration, route of administration, patient’s compliance, rescue and
adjuvant therapies, or the use of non-pharmacological therapies.
For instance, for patients with neuropathic pain and severe pain, it
might be more appropriate to add an adjuvant drug for
neurophatic pain rather than changing the type of analgesic drugs
or increase its dosage. Eventually, PMI is a static measure that
allows cross-sectional evaluation, but cannot adequately assess
events over time. Given the longitudinal nature of the study, we
were also able to prospectively evaluate the PMI negative status at
4 weeks. As expected, as it is very sensitive to the administration of
opioids, the proportion of undertreatment falls substantially
approaching 5%, with little variability across variables (type of
centre and patient). As a conclusion, PMI can be viewed as a
preliminary indicator (a screener) of potential undertreatment that
requires a further more specific evaluation.
When we used a selected list of indicators to describe the
attitude of Italian physicians towards treating subgroups of
patients with specific clinical conditions, we found that the general
picture captured by PMI does reflect substantial undertreatment.
These indicators also added important information about less than
optimal practices. Only 59% of patients with severe worst pain
actually received a strong opioid as ‘around the clock therapy’
at the time of study enrolment, 44% with neuropathic pain had
an adjuvant drug prescribed and 24% with breakthrough pain
had a ‘rescue’ analgesic. The interpretation of the fact that only
38% of patients with bone metastasis actually were receiving
bisphosphonates is less straightforward as the role of these
drugs to obtain immediate pain relief remains uncertain, despite
results from a Cochrane Review document that the addition
of bisphosphonates can be beneficial (Wong and Wiffen, 2002).
Interestingly, also these indicators were associated with the place
of care.
In summary, in this prospective observational study, the PMI
method indicated a high prevalence of analgesic undertreatment in
Italy, around 50% in some subgroups, which varies according to
several factors related to the characteristics of the cases and to
some structural and organisation variables. These findings confirm
the results of a systematic review (Deandrea et al, 2008). Other
clinical indicators suggest that undertreatment is substantial in
some specific subgroups, with underuse of specific adjuvant drugs.
Recourse to the WHO third-level drugs is still delayed in a large
percentage of patients with cancer pain, half of whom are still
treated with anticancer drugs, but very few (31%) had adequate
information about prognosis.
It is likely that after the first impact of the WHO guidelines on
cancer pain after their first publication in 1986, the present overall
strategy for managing cancer pain in Italy would need more
structured interventions to improve and standardise quality of
Recruitment Adjuvant Time of
Lower % Upper Overall = 25.2% center
Hospice No
Yes
Yes
Yes
Yes
Yes
Yes
New 11.6
4.7
6.8
30.4
20.0 33.3
0.7 9.8 18.8
46.8 55.3 64.0
20.5 30.5 40.5
26.7 35.3 44.0
27.1 39.3 51.6
7.7 11.8 15.9
26.4 31.2 36.0
16.8 26.2 35.6
13.2 16.3 19.4
01 0 2 0 3 0
% PMI-
40 50 60 70
17.1
49.2
29.6
New
New
New
New
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Figure 3 Percentages (95% confidence interval) of patients with negative PMI in all the combinations among levels of recruiting centres, adjuvant therapy
and time of recruiting.
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scare. Evidences about the most effective interventions in changing
the outcome of current practice in cancer pain management are
scarce. Although guidelines implementation proved to have an
impact on patient-reported outcomes (Ventafridda et al, 1990; Du
Pen et al, 1999), educational and quality improvement pro-
grammes had no effect in modifying patients’ pain severity, but a
beneficial effect was seen as the result of providing specialised
palliative care (Goldberg and Morrison, 2007). Others have
advocated the efficacy of the implementation of institutional
policies, adoption of clinical pathways and pain consultation
models (Brink-Huis et al, 2008). In Italy where lack of
homogeneous service development for patients with cancer pain,
cultural barriers and poor guidelines dissemination are likely to
exist, a combination of approaches adopted by professional and
scientific associations, regulatory authorities and institutions
could improve the way in which the pain is managed in this
patient population.
Our results also support the idea that palliative care, like the
prevention and relief of symptoms in cancer patients, needs to be a
component of patient care also during anticancer treatment, and
not merely at the end of life. A wider approach is therefore needed,
with better education on palliative care and pain management to
improve the use of opioids, to standardise the practice of
managing cancer pain to minimum standards (Maltoni, 2008;
Meyers et al, 2004) and to improve the physician–patient
communication (Harrington and Smith, 2008).
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Table 6 Compliance with selected indications according to specific subgroups
Type of patient Type of centre
ALL New patients Already admitted Wald v
2 P-value Oncology Pain Palliative care Hospice Wald v
2 P-value
a
Breakthrough pain
Rescue (no)
n 663 174 474 5.13 0.0236 367 138 105 53 1.87 0.6008
% 76.2 82.1 73.9 75.5 79.8 76.1 72.6
Rescue (yes)
n 207 38 167 119 35 33 20
% 23.8 17.9 26.1 24.5 20.2 23.9 27.4
Total 870 212 641 486 173 138 73
Neuropathic pain
Adjuvant (no)
n 252 65 180 3.68 0.0547 154 34 51 13 11.37 0.0099
% 55.4 63.1 52.3 61.8 42.5 53.1 43.3
Adjuvant (yes)
n 203 38 164 95 46 45 17
% 44.6 36.9 47.7 38.2 57.5 46.9 56.7
Total 455 103 344 249 80 96 30
Bone metastasis
Bisphosphonates (no)
n 522 159 354 34.91 o0.0001 252 108 93 69 50.55 o0.0001
% 62.0 80.3 56.1 52.0 75.5 69.4 86.3
Bisphosphonates (yes)
n 320 39 277 233 35 41 11
% 38.0 19.7 43.9 48.0 24.5 30.6 13.8
Total 842 198 631 485 143 134 80
Worst pain 47
Around the clock therapy (no)
n 327 140 178 25.91 o0.0001 174 64 75 14 12.61 0.0056
% 40.9 53.2 34.2 38.7 43.2 51.0 25.5
Around the clock therapy (yes)
n 473 123 343 276 84 72 41
% 59.1 46.8 65.8 61.3 56.8 49.0 74.5
Total 800 263 521 450 148 147 55
aLogistic regression test.
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